439692-69-0 Usage
Uses
Used in Pharmaceutical Research:
Thieno[2,3-d]pyrimidin-4(1H)-one, 6-methyl-, hydrazone is used as a research compound for its potential role in drug discovery and development. Thieno[2,3-d]pyrimidin-4(1H)-one, 6-methyl-, hydrazone's diverse biological activities, including antimicrobial, antitumor, and anti-inflammatory properties, make it a valuable asset in the search for new therapeutic agents.
Used in Medical Research:
In the medical research field, Thieno[2,3-d]pyrimidin-4(1H)-one, 6-methyl-, hydrazone is utilized to explore its potential applications in treating various diseases and conditions. Its unique structure and biological activities suggest that it could contribute to advancements in medical treatments.
Further research is necessary to fully understand the compound's properties and to determine its suitability for specific applications in the pharmaceutical and medical industries. The exploration of Thieno[2,3-d]pyrimidin-4(1H)-one, 6-methyl-, hydrazone's potential could lead to the development of new drugs and therapies that address unmet medical needs.
Check Digit Verification of cas no
The CAS Registry Mumber 439692-69-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,3,9,6,9 and 2 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 439692-69:
(8*4)+(7*3)+(6*9)+(5*6)+(4*9)+(3*2)+(2*6)+(1*9)=200
200 % 10 = 0
So 439692-69-0 is a valid CAS Registry Number.
439692-69-0Relevant academic research and scientific papers
Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of Cyclin D1-CDK4: Synthesis, biological evaluation, and structure-activity relationships
Horiuchi, Takao,Chiba, Jun,Uoto, Kouichi,Soga, Tsunehiko
scheme or table, p. 305 - 308 (2011/02/28)
The synthesis and evaluation of new analogues of thieno[2,3-d]pyrimidin-4-yl hydrazones are described. 2-Pyrdinecarboxaldehyde [6-(tert-butyl)thieno[2,3-d]pyrimidine-4-yl]hydrazone derivatives have been identified as cyclin-dependent kinase 4 (CDK4) inhibitors. The potency, selectivity profile, and structure-activity relationship of this series of compounds are discussed.
